Efficacy and tolerability of losartan in hypertensive patients with renal impairment

Robert Toto, Pamela Shultz, Leopoldo Raij, Helen Mitchell, Wayne Shaw, Denise Ramjit, Jenny Toll, Shahnaz Shahinfar

Research output: Contribution to journalArticle

76 Citations (Scopus)

Abstract

We evaluated the blood pressure-lowering activity, tolerability, and safety of losartan in 112 hypertensive (sitting diastolic blood pressure, 90 to 115 mm Hg) patients with chronic renal insufficiency including mild renal insufficiency (30 to 60 mL/min per 1.73 m2; n=51), moderate to severe renal insufficiency (10 to 29 mL/min per 1.73 m2; n=33), or hemodialysis (n=28). After a 3-week placebo period, once-daily losatan was administered for 12 weeks. The daily dose of 50 mg was increased to 100 mg after 4 weeks in patients whose sitting diastolic blood pressure remained ≤90 mm Hg or was reduced by <5 mm Hg. A second, non-angiotensin-converting enzyme inhibitor, antihypertensive drug was added after 8 weeks as needed. Twenty-four-hour creatinine clearance was determined and renal clearance studies of inulin and para-aminohippurate were done in a subset of 11 patients. Trough sitting blood pressures were reduced at the end of the first week in all groups. At weeks 4, 8, and 12, the reductions in systolic blood pressure/diastolic blood pressure averaged - 11.9/-8.7, - 10.8/-9.4, and - 14.7/- 12.1 mm Hg in patients with mild renal insufficiency; -7.7/-6.3, - 13.1/ -11.8, and - 14.1/-10.6 mm Hg, in moderate to severe renal insufficiency; -17.0/-12.7, - 19.1/-14.4, and -22.7/-18.0 mm Hg in hemodialysis. Creatinine clearance, glomerular filtration rate, and effective renal plasma flow were stable. Losartan was withdrawn in only 6 patients because of a clinical or laboratory adverse experience. Hyperkalemia (>6 mEq/L) requiring discontinuation of losartan occurred in only one (group 2) patient. We conclude that once-daily losartan, given as monotherapy at doses of 50 or 100 mg or in combination with other antihypertensive drugs, was effective in reducing blood pressure in hypertensive patients with chronic renal disease and that losartan regimens were well tolerated in all groups, including those on hemodialysis.

Original languageEnglish
Pages (from-to)684-691
Number of pages8
JournalHypertension
Volume31
Issue number2
StatePublished - Feb 1 1998
Externally publishedYes

Fingerprint

Losartan
Blood Pressure
Kidney
Chronic Renal Insufficiency
Renal Insufficiency
Renal Dialysis
Antihypertensive Agents
Placebos
Safety

Keywords

  • Angiotensin II
  • Hemodialysis
  • Losartan
  • Renal insufficiency
  • Renin- angiotensin-aldosterone system

ASJC Scopus subject areas

  • Internal Medicine

Cite this

Toto, R., Shultz, P., Raij, L., Mitchell, H., Shaw, W., Ramjit, D., ... Shahinfar, S. (1998). Efficacy and tolerability of losartan in hypertensive patients with renal impairment. Hypertension, 31(2), 684-691.

Efficacy and tolerability of losartan in hypertensive patients with renal impairment. / Toto, Robert; Shultz, Pamela; Raij, Leopoldo; Mitchell, Helen; Shaw, Wayne; Ramjit, Denise; Toll, Jenny; Shahinfar, Shahnaz.

In: Hypertension, Vol. 31, No. 2, 01.02.1998, p. 684-691.

Research output: Contribution to journalArticle

Toto, R, Shultz, P, Raij, L, Mitchell, H, Shaw, W, Ramjit, D, Toll, J & Shahinfar, S 1998, 'Efficacy and tolerability of losartan in hypertensive patients with renal impairment', Hypertension, vol. 31, no. 2, pp. 684-691.
Toto R, Shultz P, Raij L, Mitchell H, Shaw W, Ramjit D et al. Efficacy and tolerability of losartan in hypertensive patients with renal impairment. Hypertension. 1998 Feb 1;31(2):684-691.
Toto, Robert ; Shultz, Pamela ; Raij, Leopoldo ; Mitchell, Helen ; Shaw, Wayne ; Ramjit, Denise ; Toll, Jenny ; Shahinfar, Shahnaz. / Efficacy and tolerability of losartan in hypertensive patients with renal impairment. In: Hypertension. 1998 ; Vol. 31, No. 2. pp. 684-691.
@article{22f5f29e3f104dcb8c2d6869e9375198,
title = "Efficacy and tolerability of losartan in hypertensive patients with renal impairment",
abstract = "We evaluated the blood pressure-lowering activity, tolerability, and safety of losartan in 112 hypertensive (sitting diastolic blood pressure, 90 to 115 mm Hg) patients with chronic renal insufficiency including mild renal insufficiency (30 to 60 mL/min per 1.73 m2; n=51), moderate to severe renal insufficiency (10 to 29 mL/min per 1.73 m2; n=33), or hemodialysis (n=28). After a 3-week placebo period, once-daily losatan was administered for 12 weeks. The daily dose of 50 mg was increased to 100 mg after 4 weeks in patients whose sitting diastolic blood pressure remained ≤90 mm Hg or was reduced by <5 mm Hg. A second, non-angiotensin-converting enzyme inhibitor, antihypertensive drug was added after 8 weeks as needed. Twenty-four-hour creatinine clearance was determined and renal clearance studies of inulin and para-aminohippurate were done in a subset of 11 patients. Trough sitting blood pressures were reduced at the end of the first week in all groups. At weeks 4, 8, and 12, the reductions in systolic blood pressure/diastolic blood pressure averaged - 11.9/-8.7, - 10.8/-9.4, and - 14.7/- 12.1 mm Hg in patients with mild renal insufficiency; -7.7/-6.3, - 13.1/ -11.8, and - 14.1/-10.6 mm Hg, in moderate to severe renal insufficiency; -17.0/-12.7, - 19.1/-14.4, and -22.7/-18.0 mm Hg in hemodialysis. Creatinine clearance, glomerular filtration rate, and effective renal plasma flow were stable. Losartan was withdrawn in only 6 patients because of a clinical or laboratory adverse experience. Hyperkalemia (>6 mEq/L) requiring discontinuation of losartan occurred in only one (group 2) patient. We conclude that once-daily losartan, given as monotherapy at doses of 50 or 100 mg or in combination with other antihypertensive drugs, was effective in reducing blood pressure in hypertensive patients with chronic renal disease and that losartan regimens were well tolerated in all groups, including those on hemodialysis.",
keywords = "Angiotensin II, Hemodialysis, Losartan, Renal insufficiency, Renin- angiotensin-aldosterone system",
author = "Robert Toto and Pamela Shultz and Leopoldo Raij and Helen Mitchell and Wayne Shaw and Denise Ramjit and Jenny Toll and Shahnaz Shahinfar",
year = "1998",
month = "2",
day = "1",
language = "English",
volume = "31",
pages = "684--691",
journal = "Hypertension",
issn = "0194-911X",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Efficacy and tolerability of losartan in hypertensive patients with renal impairment

AU - Toto, Robert

AU - Shultz, Pamela

AU - Raij, Leopoldo

AU - Mitchell, Helen

AU - Shaw, Wayne

AU - Ramjit, Denise

AU - Toll, Jenny

AU - Shahinfar, Shahnaz

PY - 1998/2/1

Y1 - 1998/2/1

N2 - We evaluated the blood pressure-lowering activity, tolerability, and safety of losartan in 112 hypertensive (sitting diastolic blood pressure, 90 to 115 mm Hg) patients with chronic renal insufficiency including mild renal insufficiency (30 to 60 mL/min per 1.73 m2; n=51), moderate to severe renal insufficiency (10 to 29 mL/min per 1.73 m2; n=33), or hemodialysis (n=28). After a 3-week placebo period, once-daily losatan was administered for 12 weeks. The daily dose of 50 mg was increased to 100 mg after 4 weeks in patients whose sitting diastolic blood pressure remained ≤90 mm Hg or was reduced by <5 mm Hg. A second, non-angiotensin-converting enzyme inhibitor, antihypertensive drug was added after 8 weeks as needed. Twenty-four-hour creatinine clearance was determined and renal clearance studies of inulin and para-aminohippurate were done in a subset of 11 patients. Trough sitting blood pressures were reduced at the end of the first week in all groups. At weeks 4, 8, and 12, the reductions in systolic blood pressure/diastolic blood pressure averaged - 11.9/-8.7, - 10.8/-9.4, and - 14.7/- 12.1 mm Hg in patients with mild renal insufficiency; -7.7/-6.3, - 13.1/ -11.8, and - 14.1/-10.6 mm Hg, in moderate to severe renal insufficiency; -17.0/-12.7, - 19.1/-14.4, and -22.7/-18.0 mm Hg in hemodialysis. Creatinine clearance, glomerular filtration rate, and effective renal plasma flow were stable. Losartan was withdrawn in only 6 patients because of a clinical or laboratory adverse experience. Hyperkalemia (>6 mEq/L) requiring discontinuation of losartan occurred in only one (group 2) patient. We conclude that once-daily losartan, given as monotherapy at doses of 50 or 100 mg or in combination with other antihypertensive drugs, was effective in reducing blood pressure in hypertensive patients with chronic renal disease and that losartan regimens were well tolerated in all groups, including those on hemodialysis.

AB - We evaluated the blood pressure-lowering activity, tolerability, and safety of losartan in 112 hypertensive (sitting diastolic blood pressure, 90 to 115 mm Hg) patients with chronic renal insufficiency including mild renal insufficiency (30 to 60 mL/min per 1.73 m2; n=51), moderate to severe renal insufficiency (10 to 29 mL/min per 1.73 m2; n=33), or hemodialysis (n=28). After a 3-week placebo period, once-daily losatan was administered for 12 weeks. The daily dose of 50 mg was increased to 100 mg after 4 weeks in patients whose sitting diastolic blood pressure remained ≤90 mm Hg or was reduced by <5 mm Hg. A second, non-angiotensin-converting enzyme inhibitor, antihypertensive drug was added after 8 weeks as needed. Twenty-four-hour creatinine clearance was determined and renal clearance studies of inulin and para-aminohippurate were done in a subset of 11 patients. Trough sitting blood pressures were reduced at the end of the first week in all groups. At weeks 4, 8, and 12, the reductions in systolic blood pressure/diastolic blood pressure averaged - 11.9/-8.7, - 10.8/-9.4, and - 14.7/- 12.1 mm Hg in patients with mild renal insufficiency; -7.7/-6.3, - 13.1/ -11.8, and - 14.1/-10.6 mm Hg, in moderate to severe renal insufficiency; -17.0/-12.7, - 19.1/-14.4, and -22.7/-18.0 mm Hg in hemodialysis. Creatinine clearance, glomerular filtration rate, and effective renal plasma flow were stable. Losartan was withdrawn in only 6 patients because of a clinical or laboratory adverse experience. Hyperkalemia (>6 mEq/L) requiring discontinuation of losartan occurred in only one (group 2) patient. We conclude that once-daily losartan, given as monotherapy at doses of 50 or 100 mg or in combination with other antihypertensive drugs, was effective in reducing blood pressure in hypertensive patients with chronic renal disease and that losartan regimens were well tolerated in all groups, including those on hemodialysis.

KW - Angiotensin II

KW - Hemodialysis

KW - Losartan

KW - Renal insufficiency

KW - Renin- angiotensin-aldosterone system

UR - http://www.scopus.com/inward/record.url?scp=0031951792&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031951792&partnerID=8YFLogxK

M3 - Article

C2 - 9461241

AN - SCOPUS:0031951792

VL - 31

SP - 684

EP - 691

JO - Hypertension

JF - Hypertension

SN - 0194-911X

IS - 2

ER -